Publications

PUBLICATIONS (since inception of the Center for Cardiovascular Diseases) 

1.  Adedapo A, Oyekan A. Effects of fenofibrate, a PPAR-α ligand, on the hemodynamics of glycerol-induced renal failure in rats. Hum Exp Toxicol. 2012 Aug 2. [Epub ahead of  print]

2. Yakubu MA, Sofola OA, Igbo I, Oyekan AO. Impaired endothelium-dependent and-independent relaxation of aorta from diabetic rats. Bratisl Lek Listy.2012;113(2):59-63

3. Oyekan A PPARs and their effects on the cardiovascular system. Clin Exp Hypert 1-7, 2011.

4. Fidelis P, Wilson L, Thomas K, Villalobos M, Oyekan AO. Renal function and vasomotor activity in mice lacking the Cyp4a14 gene Exp Biol Med. 2010;235(11):1365-74.

5. Yakubu MA, Nsaif RH, Oyekan AO Regulation of cerebrovascular endothelial peroxisopme proliferator activated receptor alpha expression and nitric oxide production by clofibrate. Bratisi Lek Listy, 111: 258-264 (2010).

 6. Newaz M, Yousefipour Z, Oyekan A Natriuretic and renoprotective effect of chronic oral neutral endopeptidase inhibition in acute renal failure Ren Fail.,32:384-90, 2010

7. Yousefipour Z, Oyekan A, Newaz M. Interaction of oxidative stress, nitric oxide and  peroxisome proliferator activated receptor y in acute renal failure. Pharmacol Ther 125:436-45, 2010.

8. Zivar Yousefipour, Adebayo Oyekan, and Mohammad Newaz Role of G-protein coupled receptor kinase-2 (GRK2) in PPAR-mediated modulation of blood pressure and renal vascular reactivity in SHR. Am J Neph 2009; 30:201-208.

9. Newaz A, Ranganna K, Truong L, Oyekan A Effect of PPAR siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet. J Hypert (2009 Oct  14. [Epub ahead of print])

10. Yousefipour Z, Oyekan A, and Newaz M (2009) Role of G-protein coupled receptor kinase-2 (GRK2) in PPAR-mediated modulation of blood pressure and renal vascular reactivity in SHR. Am J Neph 30:201-208

11. Newaz A, Ranganna K, Truong L, Oyekan A (2009) Effect of PPAR a siRNA on  hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet. J Hypert (In Press)

12. Oyekan AO(2009 ) Peroxisome proliferator activated receptors – The new frontiers in the treatment of cardiovascular diseases – (Editorial article) Trop J Pharm Res 8: 101-3.

13. Yousefipour Z, Oyekan A, and Newaz M (2009) Role of G-protein coupled receptor kinase-2 (GRK2) in PPAR g-mediated modulation of blood pressure and renal vascular reactivity in SHR. Am J Neph 30:201-208.

14. Banks T, Hussain T, and Oyekan A (2008) PPAR a activation attenuated AT 1- but enhanced AT 2-mediated hemodynamic effects to angiotensin II in the rat. J Hypert. 26: 468-77, 2008.

15. Obih P andOyekan AO Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARα null mice (2008). Blood Pressure 17: 55-63.

16. Yousefipour Z, Hercule H, Oyekan AO Newaz MA (2007) Antioxidant U74389G improves glycerol-induced acute renal failure without affecting PPAR g gene. Ren Fail 29(7)

17. Yousefipour Z, Hercule C, Truong L, Oyekan AO, Newaz MA (2007) Ciglitazone, a PPAR{gamma} Inducer, ameliorates renal pre-glomerular production and activity of Angiotensin II and TxA 2 in glycerol-induced acute renal failure. J Pharmacol Exp Ther. 322: 461-8.

18. Yakubu MA, Nsaif R, Oyekan AO (2007) PPAR a activation-mediated regulation of ET-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture. J Pharmacol Exp Ther 320(2):774-81.

19. Mohammad A. Newaz, Zivar Yousefipour, and Oyekan A (2006). Oxidative-stress associated vascular aging is not NAD(P)H oxidase- but xanthine oxidase-dependent. J Cardiovasc Pharmacol 48(3):88-94.

20. Williams J, Bogwu J, and Oyekan A (2006) The role of RhoA/Rho-kinase signaling pathway in renal vascular reactivity in eNOS null mice. J Hypert 24(7):1429-36, 2006 ( Manuscript attracted Editorial Comments)

21. Ajayi AA, Fidelis P (2006) The effect of flutamide on systemic and renal hemodynamics in Zucker diabetic rats: paradoxic renal vasodilator response to endothelin-1 and TXA2 receptor activation in female sex. J Cardiovasc Pharmacol, 48(5):191-8.

22. Blanton A, Nsaif R, Hercule H, and Oyekan A (2006) Nitric oxide/cytochrome P450 interactions in cyclosporin A-induced effects in the rat. J Hypert 24(9):1865-72, 2006. 23. Newaz MA, Yousefipour Z, Oyekan AO. Role of PPAR g on the pathogenetic and vascular changes in glycerol-induced acute renal failure. Pharmacol Res 54(3):234-40, 2006

24. Long DA, Newaz MA, Prabhakar SS, Price KL, Truong LD, Feng LL, Mu W, Oyekan AO, Johnson RJ. Loss of Nitric Oxide and Endothelial Derived Hyperpolarizing Factor Mediated Responses in Aging. Kidney Intern 68(5):2154-63, 2005.

25. Newaz MA, Blanton A, and Fidelis P, Oyekan AO (2005) NAD(P)H oxidase/ nitric oxide interactions in peroxisome proliferator activated receptor (PPAR) a-mediated cardiovascular effects. Mut. Res. 579(1-2):163-71.

26. Oyekan AO Differential effects of 20-hydroxyeicosatetraenoic acid (20-HETE) on intrarenal blood flow in the rat (2005) J Pharmacol Exp Ther. 313(3):1289-95.

27. Newaz MA, Ranganna K, Oyekan AO (2004) Relationship between PPARalpha activation and NO on proximal tubular Na + transport in the rat. BMC Pharmacol., 6: 1-9.

28. Yakubu MA, Sofola OA, Igbo I, Oyekan AO Link between free radicals and protein kinase C in glucose-induced alteration of vascular dilation Life Sci. 75(24):2921-32 (2004).

29. Oyekan AO, Newaz MA, Blanton A, and Fidelis P Transcription factors and their contribution to DOCA/salt hypertension. Proc. 23rd Europ. Conf. Microcirc.(Editors, JM e Silva, C Saldanha, V Oliveira, A Prie, and A Shore) pp. 121- 126 (2004).

30. Yakubu MA, Sofola OA, Igbo I, Oyekan AO Link between free radicals and protein kinase C in glucose-induced alteration of vascular dilation Life Sci. 75(24):2921-32 (2004).

31. Ajayi AA, Ogungbade GO, Hercule HC, Oyekan AO and Mutembei L. Alteration in endothelin receptor subtype responsiveness and in the endothelin-TxA2 mimetic U46619 interaction in type-2 hypertensive diabetic Zucker rats. Diabetes Res. Clin. Pract. 63: 155-69, 2004.

32. Ajayi AA, Hercule H, Cory J, Hayes BE, and Oyekan AO Gender difference in vascular and platelet reactivity to thromboxane A2-mimetic U46619 and to endothelial dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats. Diabetes Res. Clin. Pract. 59: 11-24, 2003.

33. Newaz MA, Ranganna K, and Oyekan AO Relationship between PPARalpha activation and NO on proximal tubular Na+ transport in the rat. BMC Pharmacol., 6: 1-9, 2004.

34. Sacerdoti D, Abraham NG, Oyekan AO, Yang L, Gatta A, McGiff JC Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. J Pharmacol Exp Ther.308(2):636-43, 2004
35. Ajayi AA, Ogungbade GO, Okorodudu AO (2004) Sex hormone regulation of systemic endothelial and renal microvascular reactivity in type-2 diabetes: studies in gonadectomized and sham-operated Zucker diabetic rats. Eur J Clin Invest, 34(5):349-57.

36. Ogungbade GO, Akinsanmi LA, Jiang H, and Oyekan AO The role of epoxyeicosatrienoic acids in the renal functional response to inhibition of nitric oxide production in the rat. Am. J. Physiol., 285: F955-64, 2003.

37. Udosen IT, Hercule HC, Jiang H, and Oyekan AO Nitric oxide/epoxygenase interactions and arachidonate-induced dilation of the renal microvessel of the rat. Am. J. Physiol.. 285: H2054-63, 2003

38. Hercule HC, Wang MH, and Oyekan AO Contribution of cytochrome P450 4A isoforms to renal functional response to inhibition of nitric oxide production in the rat. J. Physiol (Lond)551: 971-9 (2003).

39. Newaz MA Yousefippour Z., Truong L., and Oyekan AO Chronic endopeptidase inhibition in DOCA-salt hypertension: Mechanism of cardiovascular protection. Clin Exp Hypert. 25: 335-347 (2003).

40. Sofola OA, Yakubu MA, Igbo I, Newaz MA, and Oyekan AO High salt diet modulates cAMP- and nitric oxide-mediated relaxation responses to isoproterenol in the rat aorta. Eur. J. Pharmacol. 474: 241-247 (2003).

41. Oyekan AO Contributions of nitric oxide and prostanoids and their signaling pathways to the renal medullary vasodilator effect of U46619 (9-11-dideoxy-11 a,9a-epoxymethano-prostaglandin F 2a ) in the rat. J. Pharmacol. Exp. Ther.,304: 507-512 (2003).

42. Ajayi AA, Hercule HC, Cory J, Hayes BC, and Oyekan AO Gender differences in vascular and platelet reactivity to TxA 2 mimetic U46619 and to endothelial-dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats. Diab. Res. Clin. Pract.,59: 11-24, 2003.

43. Ajayi AA, Newaz M, Hercule H, Saleh M, Bode CO, Oyekan AO (2003) Endothelin-like action of Pausinystalia yohimbe aqueous extract on vascular and renal regional hemodynamics in Sprague Dawley rats. Methods Find Exp Clin Pharmacol, 25(10):817-22.

44. Carroll MA, Ferreri NR, Escalante BE, Oyekan AO,and McGiff JC. Cytochrome P450 arachidonic acid metabolites modulate renal tubular function. Adv. Prostaglandin Leuk.and Other Bioactive Lipid Research: Basic Science and Clinical Applications. P67-p69,Ed Yazici et al, 2002. (Kluwer Academic/Plenum Publishers, London, UK).

45. Oyekan AO Nitric oxide inhibits renal cytochrome P450-dependent epoxygenases in the rat. Clin Exp Pharmacol Physiol., 29: 990-995 (2002)

46. Newaz MA and Oyekan AOContribution of renal oxygenases to arachidonic acid-induced vasomotor responses in acute renal failure. J Cardiovasc. Pharmacol., 39: 834-841, 2002.

47. Hercule HC, Lofberg E. and Oyekan AO (2002) Renal cytochrome P450 oxygenases and preglomerular vascular response to arachidonic acid and endothelin-1 in ischemic acute renal failure. J. Pharmacol. Exp. Ther., 302: 717-724.

48. Newaz MA, Yousefiipour Z., and Oyekan AO(2002)Effects of pergolide on blood pressure and tissue injury in DOCA-salt hypertension.  Blood Pressure, 11: 1-6.

49. Escalante BE, McGiff JC and Oyekan AO (2002) Role of cytochrome P450 arachidonate metabolites in endothelin signaling in the rat proximal tubule. Am. J. Physiol., 282: F144-F150.

50. Bautista R, Sanchez A, Hernandez J, Oyekan AO,and Escalante B (2001) Angiotensin II type AT(2) receptor mRNA expression and vasodilatation are increased in renal failure. Hypertension, 38: 669-673.
51. Morgan ET, Ullrich V, Daiber A, Schmidt P, Takaya N, Sholin H, McGiff JC, Oyekan AO et al (2001) Cytochromes P450 and flavin monooxygenases – Targets and sources of nitric oxide. Drug Metab. Dispos., 29: 1366-1376.

52. Hercule HC, Ajayi AA and Oyekan AO(2001) Differential effects of U46619 on renal regional hemodynamics in the rat: Involvement of endothelin  J. Pharmacol. Exp. Ther. 299: 372-376.

53. Newaz MA and Oyekan AO (2001) Vascular responses to endothelin-1, angiotensin II, and U46619 in glycerol-induced acute renal failure J Cardiovasc. Pharmacol.. 38: 569-577.

54. Ajayi AA, Hercule HC, Pamugo, J, Dixon, D, and Oyekan AO(2001)Interactions of renin-angiotensin system and alpha-1 adrenoceptors on renal hemodynamics in healthy and acute renal failure rats: The role of nitric oxide. Blood Pressure10: 1-9.

55. Adeagbo ASO, Oyekan AO, Joshua IG, Falkner KC, Prough RA and Pierce WM, Jnr. (2001) Epoxyeicotrienoic acid release mediates nitric oxide-independent dilatation of rat mesenteric vessels. In: EDHF 2000, Chapter 22, pages 195-206. Taylor and Francis, London Publishers.

56. Hercule HC and Oyekan AO(2000) The role of nitric oxide and cytochrome P450-derived eicosanoids in endothelin-1-induced changes in intrarenal hemodynamics in the rat. Am. J. Physiol., 279: R2132-2141 (2000).

57. Oyekan AO(2000) Cytochrome P450-dependent metabolites of arachidonic acid and renal function in the rat. Clin. Exp. Pharmacol. Physiol., 27: 521-526

58. Hercule HC and Oyekan AO (2000) Cytochrome P450 } {1 hydroxylase-derived eicosanoids contribute to ETA- and ETB-receptor-mediated vasoconstriction to Endothelin-1 In the rat preglomerular arteriole. J. Pharmacol. Exp. Ther.,292: 1153-1160.